TIVC News

Tivic Health Systems, which makes a non-invasive neuromodulation device for sinus and nasal inflammation, raised $15 million by offering 3 million shares at $5, the low end of the range of $5 to $6. The company offered 0.3 million more shares than anticipated. At pricing, Tivic Health Systems commands a fully diluted market value of $48 million. ...read more

Tivic Health Systems, which makes a non-invasive neuromodulation device for sinus and nasal inflammation, announced terms for its IPO on Thursday. The Newark, CA-based company plans to raise $15 million by offering 2.7 million shares at a price range of $5 to $6. At the midpoint of the proposed range, Tivic Health Systems would command a fully diluted market value of $51 million. ...read more

After a busy July, the IPO market began to pump the brakes this past week with four IPOs and four postponements. SPAC activity remained steady with seven blank check IPOs. New filers trickled into the IPO pipeline, with only one IPO and six SPACs submitting initial filings.     Four companies postponed: biopharmaceutical royalty company ...read more

Tivic Health Systems, which is commercializing a bioelectronic device for sinus and nasal inflammation, filed on Tuesday with the SEC to raise up to $16 million. Tivic is a commercial-phase bioelectronic medicine company focused on inflammation. Its first product, ClearUP Sinus Relief, is a patented handheld device that uses ultra-low current electrical waves to relieve symptoms of...read more